[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:esophageal-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":312,"states":335},"Esophageal Carcinoma",128,114,[8,16,22,29,36,42,48,54,60,67,73,78,85,91,97,103,109,115,121,127,133,139,145,151,157,163,168,174,180,186,192,198,204,210,216,222,228,234,240,246,252,258,265,270,276,282,288,294,300,306],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04846309","Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy",[12],"Phase 1","RECRUITING","2026-08-26T02:18:00.873391Z","2026-06-18T12:24:02.912731Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06414902","18F-AraG PET\u002FCT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer",[12],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:28.819164Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04018872","Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer",[26],"Phase 2","2026-08-26T02:18:06.247899Z","2026-05-05T02:43:28.803839Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05906134","Minimally Invasive Esophagectomy Pain Control Trial",[33],"Phase 1\u002FPhase 2","2026-08-26T02:18:29.369233Z","2026-05-05T02:43:28.533490Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT01684904","Proton Therapy for Esophageal Cancer",[],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.487827Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06906887","PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer",[26],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:27.928813Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07070466","Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA",[26],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:27.739752Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT07532902","A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer",[12],"2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.689344Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT05183126","Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer",[64],"Phase 4","2026-08-26T02:17:55.355429Z","2026-05-05T02:43:29.697095Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05332002","sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)",[26],"2026-08-26T02:15:28.524219Z","2026-05-05T02:43:29.671133Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":34,"content_modified":77},"NCT06469944","Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable\u002FMetastatic Gastroesophageal Adenocarcinoma (MK-3475-06C\u002FKEYMAKER-U06)",[33],"2026-05-05T02:43:29.662119Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":83,"content_modified":84},"NCT07431281","Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2",[82],"Phase 3","2026-08-26T02:16:04.914942Z","2026-05-05T02:43:29.651140Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07181473","A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced\u002FMetastatic Solid Tumors",[12],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.170836Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07001592","Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors",[12],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.887551Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT04379596","Ph1b\u002F2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)",[26],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.509515Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT05187182","CA-4948 in Combination With FOLFOX\u002FPD-1 Inhibitor +\u002F- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer",[12],"2026-08-26T02:18:20.384845Z","2026-05-05T02:43:26.773275Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06123338","A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer",[26],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:26.678269Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT03526835","A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",[33],"2026-08-26T02:17:16.126291Z","2026-07-30T01:46:14.461456Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06293898","Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors",[12],"2026-08-26T02:16:23.080181Z","2026-07-24T01:27:14.888332Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[33],"2026-08-26T02:18:52.966503Z","2026-06-17T02:29:30.060269Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT07594626","BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion",[33],"2026-08-26T02:17:39.048487Z","2026-05-29T15:36:40.204907Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT07578571","A Phase 1 Study of IM-1617 in Participants With Advanced Cancer",[12],"2026-08-26T02:18:48.678868Z","2026-05-29T15:36:40.196396Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT07197671","Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer",[12],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.735881Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05902988","A Phase I\u002FII Study of VLS-1488 in Subjects With Advanced Cancer",[33],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:29.683485Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT06444815","A Study of VET3-TGI in Patients With Solid Tumors",[12],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:29.507169Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":89,"content_modified":167},"NCT06239194","Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors",[33],"2026-05-05T02:43:29.493268Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT07132918","HEARTS Trial for Thoracic Cancers",[26],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:29.372446Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT06065371","Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy",[12],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:29.211761Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT07223424","Patient Preference for Subcutaneous vs. Intravenous Immune Therapy",[26],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:29.166586Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT05274048","Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients",[12],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:28.987899Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT06562179","A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease",[],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:28.837002Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT06695845","A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",[26],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.744064Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT05983432","Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors",[12],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.678419Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT06673329","Brodalumab in the Treatment of Immune-Related Adverse Events",[12],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:28.645184Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT03740256","Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",[12],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:28.644039Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT06910657","IDOV-Immune for Advanced Solid Tumors",[12],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:28.638930Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT05101070","S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors",[33],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:28.621667Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT06943521","A Study of MT-4561 in Patients With Various Advanced Solid Tumors",[33],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:28.477669Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT06710756","Lead-212 PSV359 Therapy for Patients With Solid Tumors",[33],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:28.400599Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT06172478","A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors",[26],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:28.357224Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":256,"content_modified":257},"NCT07227168","A Study of STRO-004 in Adults With Refractory\u002FRecurrent Metastatic Cancer",[12],"2026-08-26T02:16:22.235886Z","2026-05-05T02:43:28.314526Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":263,"content_modified":264},"NCT06367972","A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)",[262],"Phase 2\u002FPhase 3","2026-08-26T02:16:11.347936Z","2026-05-05T02:43:28.171596Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":155,"content_modified":269},"NCT07213791","A Study of LY4337713 in Participants With FAP-Positive Solid Tumors",[12],"2026-05-05T02:43:28.120672Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":274,"content_modified":275},"NCT06465069","A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors",[12],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:27.622410Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":280,"content_modified":281},"NCT07090499","A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors",[12],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:27.475428Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":286,"content_modified":287},"NCT06959706","Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:27.446259Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":292,"content_modified":293},"NCT07016971","CBG\u002FCBD Oil for Chemotherapy-Induced Peripheral Neuropathy",[12],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:27.436153Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT05581004","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",[12],"2026-08-03T03:43:00.111924Z","2026-05-05T02:43:27.397730Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":304,"content_modified":305},"NCT05005403","Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan",[12],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.253319Z",{"nct_id":307,"title":308,"phases":309,"status":13,"updated_at":310,"content_modified":311},"NCT05969860","At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer",[26],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:26.978986Z",[313,317,321,325,329,332],{"biomarker":314,"count":315,"slug":316},"ERBB2 Gene",7,"erbb2-gene",{"biomarker":318,"count":319,"slug":320},"MSI1 Gene",5,"msi1-gene",{"biomarker":322,"count":323,"slug":324},"MRC1 wt Allele",4,"mrc1-wt-allele",{"biomarker":326,"count":327,"slug":328},"Programmed Cell Death 1 Ligand 1",3,"programmed-cell-death-1-ligand-1",{"biomarker":330,"count":327,"slug":331},"Prolyl Endopeptidase FAP","prolyl-endopeptidase-fap",{"biomarker":333,"count":327,"slug":334},"TPM2 wt Allele","tpm2-wt-allele",[336,340,344,348,352,355,359,363,366,370,374,378,381,385,388,392,395,399,402,406,409,412,416,420],{"state":337,"count":338,"slug":339},"Texas",51,"texas",{"state":341,"count":342,"slug":343},"California",43,"california",{"state":345,"count":346,"slug":347},"Florida",32,"florida",{"state":349,"count":350,"slug":351},"New York",28,"new-york",{"state":353,"count":350,"slug":354},"Pennsylvania","pennsylvania",{"state":356,"count":357,"slug":358},"Massachusetts",25,"massachusetts",{"state":360,"count":361,"slug":362},"Colorado",21,"colorado",{"state":364,"count":361,"slug":365},"Michigan","michigan",{"state":367,"count":368,"slug":369},"Missouri",19,"missouri",{"state":371,"count":372,"slug":373},"Ohio",18,"ohio",{"state":375,"count":376,"slug":377},"Illinois",17,"illinois",{"state":379,"count":376,"slug":380},"Tennessee","tennessee",{"state":382,"count":383,"slug":384},"Minnesota",15,"minnesota",{"state":386,"count":383,"slug":387},"North Carolina","north-carolina",{"state":389,"count":390,"slug":391},"Virginia",13,"virginia",{"state":393,"count":390,"slug":394},"Wisconsin","wisconsin",{"state":396,"count":397,"slug":398},"Indiana",11,"indiana",{"state":400,"count":397,"slug":401},"Maryland","maryland",{"state":403,"count":404,"slug":405},"Arizona",10,"arizona",{"state":407,"count":404,"slug":408},"Connecticut","connecticut",{"state":410,"count":404,"slug":411},"New Jersey","new-jersey",{"state":413,"count":414,"slug":415},"Georgia",9,"georgia",{"state":417,"count":418,"slug":419},"Kentucky",8,"kentucky",{"state":421,"count":418,"slug":422},"Washington","washington"]